Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Background Blinatumomab is a BiTE(®) immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). AIMS: To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in...

Descripción completa

Detalles Bibliográficos
Autores principales: Topp, Max S., Stein, Anthony S., Gökbuget, Nicola, Horst, Heinz‐August, Boissel, Nicolas, Martinelli, Giovanni, Kantarjian, Hagop, Brüggemann, Monika, Chen, Yuqi, Zugmaier, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026950/
https://www.ncbi.nlm.nih.gov/pubmed/33734596
http://dx.doi.org/10.1002/cam4.3731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026950/
https://www.ncbi.nlm.nih.gov/pubmed/33734596
http://dx.doi.org/10.1002/cam4.3731

Ejemplares similares